Ascendiant Capital Maintains Buy on Alzamend Neuro, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 90.4%

Neg 0% Neu 0% Pos 90.4%

Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and raises the price target from $25 to $26.